Veritec (VRTC) News Today $0.0060 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Vertex grew headcount 13% for the second straight yearFebruary 18, 2025 | bizjournals.comVertex Pharma upgraded at Canaccord Genuity after Q4 resultsFebruary 12, 2025 | msn.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Call TranscriptFebruary 12, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)February 11, 2025 | markets.businessinsider.comVertex Q4 revenue beats Street, guidance in line with consensusFebruary 11, 2025 | msn.comVertex Pharmaceuticals price target raised to $520 from $460 at TruistFebruary 11, 2025 | markets.businessinsider.comVertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top EstimatesFebruary 11, 2025 | msn.comVertex Pharmaceuticals (VRTX) Sees Strong 2025 Revenue GrowthFebruary 11, 2025 | markets.businessinsider.comVertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call TranscriptFebruary 11, 2025 | finance.yahoo.comVertex stock price target raised to $520 at Truist SecuritiesFebruary 11, 2025 | msn.comVertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 50% Above Its Share PriceFebruary 10, 2025 | finance.yahoo.comVertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look ForFebruary 9, 2025 | msn.comVertex Pharmaceuticals (VRTX) Gets a Buy from J.P. MorganFebruary 8, 2025 | markets.businessinsider.comBiotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug ApprovalFebruary 5, 2025 | msn.comVertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challengesFebruary 4, 2025 | msn.comEvercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)February 3, 2025 | markets.businessinsider.comVertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in EnglandJanuary 31, 2025 | seekingalpha.comVertex Pharmaceuticals (VRTX) Initiated with a Buy at Cantor FitzgeraldJanuary 31, 2025 | markets.businessinsider.comVertex Pharmaceuticals announces Casgevy reimbursement pact with NHS EnglandJanuary 31, 2025 | markets.businessinsider.comVertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid PainkillerJanuary 31, 2025 | markets.businessinsider.comFDA Approves Vertex Pharma's JOURNAVX As The First Drug In A New Class Of Non-Opioid Pain MedicinesJanuary 31, 2025 | markets.businessinsider.comVertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain DrugJanuary 31, 2025 | msn.comVertex Pharmaceuticals’ non-opioid painkiller approved by FDA, Bloomberg saysJanuary 30, 2025 | markets.businessinsider.comVertex Pharmaceuticals announces FDA approval of JournavxJanuary 30, 2025 | markets.businessinsider.comVertex gets FDA approval for non-opioid pain relieverJanuary 30, 2025 | msn.comVertex stock price target cut to $533 by Piper SandlerJanuary 27, 2025 | msn.comVertex Pharmaceuticals' SWOT analysis: stock poised for growth amid challengesJanuary 24, 2025 | msn.comVertex Pharmaceuticals (VRTX) Receives a Hold from RBC CapitalJanuary 23, 2025 | markets.businessinsider.comVertex Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progressJanuary 21, 2025 | msn.comVertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comVertex Therapeutics: The Pain Comes With The Territory For SuzetrigineJanuary 14, 2025 | seekingalpha.comCiti Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)January 13, 2025 | markets.businessinsider.comVertex Pharmaceuticals Earnings Preview: What to ExpectJanuary 9, 2025 | msn.comThose who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) three years ago are up 79%December 31, 2024 | finance.yahoo.comRBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)December 24, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)December 24, 2024 | markets.businessinsider.comVertex wins approval for new once-daily CF drugDecember 24, 2024 | bizjournals.comBarclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)December 22, 2024 | markets.businessinsider.comVertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain StrongDecember 20, 2024 | markets.businessinsider.comVertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis TreatmentDecember 20, 2024 | markets.businessinsider.comUS FDA approves Vertex Pharma's triple combo cystic fibrosis treatmentDecember 20, 2024 | reuters.comVertex's $10 Billion Blow: Painkiller Trial Results Spark Investor PanicDecember 20, 2024 | finance.yahoo.comVertex's non-opioid drug meets main goal in mid-stage nerve pain trialDecember 19, 2024 | reuters.com$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayDecember 13, 2024 | benzinga.comVertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...December 8, 2024 | businesswire.comIs Vertex Pharmaceuticals Stock Underperforming the Dow?December 2, 2024 | msn.comIs Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?November 29, 2024 | msn.comVertex Pharmaceuticals (NASDAQ:VRTX) shareholders are still up 137% over 3 years despite pulling back 3.4% in the past weekNovember 25, 2024 | finance.yahoo.comGilead, Vertex initiated as new big biotech buys at CitiNovember 14, 2024 | msn.comVertex Pharmaceuticals price target raised to $408 from $361 at CanaccordNovember 6, 2024 | markets.businessinsider.com Get Veritec News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTC and its competitors with MarketBeat's FREE daily newsletter. Email Address VRTC Media Mentions By Week VRTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRTC News Sentiment▼0.450.67▲Average Computer and Technology News Sentiment VRTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRTC Articles This Week▼12▲VRTC Articles Average Week Get Veritec News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MetaWorks Platforms News Micromobility.com News Ucommune International News Sparta Commercial Services News Waitr News Cyber Apps World News Digital Locations News U.S. Stem Cell News SITO Mobile News MJ News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:VRTC) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veritec, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veritec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
